Sky View Investment Advisors, LLC Vertex Pharmaceuticals Inc Transaction History

Sky View Investment Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	SELL	$314.42 - $351.91 $414,405 - $463,817	-1,318 Reduced 63.79%	748 $263,000
Q1 2023 May 18, 2023	BUY	$283.23 - $323.1 $200,526 - $228,754	708 Added 52.14%	2,066 $651,000
Q4 2022 Feb 16, 2023	SELL	$285.76 - $321.48 $203,461 - $228,893	-712 Reduced 34.4%	1,358 $392,000
Q3 2022 Nov 16, 2022	BUY	$273.83 - $305.53 $99,674 - $111,212	364 Added 21.34%	2,070 $599,000
Q2 2022 Nov 15, 2022	BUY	$234.96 - $292.55 $88,344 - $109,998	376 Added 28.27%	1,706 $481,000
Q1 2022 May 17, 2022	SELL	$221.42 - $260.97 $3.3 Million - $3.89 Million	-14,920 Reduced 91.82%	1,330 $347,000
Q4 2021 Feb 18, 2022	BUY	$177.01 - $223.45 $2.88 Million - $3.63 Million	16,250 New	16,250 $269,000
Q1 2021 May 18, 2021	SELL	$207.02 - $241.31 $269,747 - $314,426	-1,303 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$207.01 - $276.09 $269,734 - $359,745	1,303 New	1,303 $308,000

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Sky View Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Sky View Investment Advisors, LLC with notifications on news.